NIH R01 · 2025
Understanding hematopoietic stem cell dysfunction in refractory Crohn's disease
Despite an unprecedented growth in Crohn's disease (CD) therapies it has remained consistent that each new therapy is less effective for patients that failed a previous therapy leaving many patients refractory to treatment. While CD therapies seemingly encompass distinct therapeutic mechanisms, all target the inflammatory response supporting that medically refractory CD involves mechanisms not directly related to inflammation. The near universal success of autologous stem cell transplantation (SCT) in refractory CD provides a rare cohort to understand therapeutic mechanisms that exist outside of the traditional CD treatment paradigm. In our study of CD patients that received a SCT we…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.